Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (256)
Cancellation by sponsor (71)
Prescription medicine registration (25)
Section 14, TGO91 consent (6)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)

Date

2024 (11)
2023 (18)
2022 (36)
2021 (70)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (14)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (3)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (5)
1998 (1)
1996 (3)
1994 (3)
1991 (11)

Results for "[search-keyword]"

Search

Sponsor content

360 result(s) found, displaying 91 to 100

Oxaliplatin APOTEX oxaliplatin 200mg/40mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
GenRx Oxaliplatin oxaliplatin 200mg/40mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TOBRAMYCIN KP tobramycin 300 mg/5 mL inhalation solution ampoule Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TOBRAMYCIN CW tobramycin 300 mg/5 mL inhalation solution ampoule Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TOBRAMYCIN AN tobramycin 300 mg/5 mL inhalation solution ampoule Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TOBRAMYCIN AMNEAL tobramycin 300 mg/5 mL inhalation solution ampoule Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
PEMETREXED ACT pemetrexed (as disodium) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
PEMETREXED ACT pemetrexed (as disodium) 500mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TIROSTAT tirofiban (as hydrochloride) 12.5mg/50mL Concentrated Injection for infusion Vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TEMOZOLOMIDE JUNO temozolomide 180 mg capsule bottle (354888)

28 April 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TEMOZOLOMIDE JUNO temozolomide 180 mg capsule bottle.

Pages

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.